Cancer Clinical Trial 20213129

[LCID Study Number: 20213129]

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

The purpose of this study is to examine how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications.

Disease/Condition: Cancer

Department: Hematology and Oncology

Location(s): Addison Gilbert Hospital; Beverly Hospital; Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody; Winchester Hospital

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421

View NCT ID 04871542 on ClinicalTrials.gov
Protocol #: 20213129
Principal Investigator(s): Krishna S. Gunturu
Trial Phase: Sponsor Initiated Study Observational